This position paper presents facts and figures regarding the evolution of interactions between pharma companies and physicians, and makes practical recommendations to ensure regular and impactful interactions in the years to come
News
Developing a strategy for rare diseases in France requires a clear understanding of the care ecosystem, key...
The French Voluntary Trade Organization (VTO) market is consolidating, making VTOs increasingly important partners for pharma companies...
« High-performance Market Access Brand Plans require method, rigor and pragmatism » Our new publication on how to build...